Negative in Ames, in vitro and in vivo micronucleus assays
“Dordaviprone was negative for mutagenicity in the Ames test and negative for clastogenicity in both the in vitro and in vivo micronucleus tests.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Carcinogenicity
Not conducted; not warranted for the proposed indication
“Carcinogenicity studies have not been conducted with dordaviprone and are not warranted for the proposed indication.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD: embryofetal mortality, growth alterations and malformations below human exposure
“In animal embryo-fetal development studies, oral administration of dordaviprone to pregnant rats and rabbits during the period of organogenesis caused embryofetal mortality, alterations to growth, and structural abnormalities at exposures below the human exposure at the highest recommended dose”
“Dordaviprone inhibited hERG potassium channel current with an IC50 of 2.4 µM in an in vitro safety pharmacology assessment. No changes were noted in ECG parameters in dogs”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Genotox: Ames
Negative
“Dordaviprone was not genotoxic in in vitro (Ames and micronucleus assay) and in vivo (mouse micronucleus) assays.”
Not conducted (not warranted for H3 K27M-mutant diffuse glioma)
“The FDA agrees that carcinogenicity studies are not warranted for the current indication of pediatric and adult patients with H3 K27M-mutant diffuse glioma.”
✓ VerifiedFDA multi-discipline review, p. 71Source ↗
Carcinogenicity timing
Not required for the indication
“The FDA agrees that carcinogenicity studies are not warranted for the current indication of pediatric and adult patients with H3 K27M-mutant diffuse glioma.”
✓ VerifiedFDA multi-discipline review, p. 71Source ↗
hERG / QT
hERG IC50 2.4 µM
“Dordaviprone inhibited hERG potassium channel current with an IC50 of 2.4 µM in an in vitro safety pharmacology assessment.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative